Publication Name	World Journal of Gastroenterology
Manuscript ID	25695
Country	Italy

Received	2016-03-21 09:23
Peer-Review Started	2016-03-22 16:18
To Make the First Decision	2016-04-14 11:14
Return for Revision	2016-04-17 17:47
Revised	2016-05-09 23:41
Second Decision	2016-06-06 08:14
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-06-15 17:48
Articles in Press	2016-06-15 17:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-07 10:22
Publish the Manuscript Online	2016-07-15 15:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Manuscript Source	Invited Manuscript
All Author List	Liliana Montella, Giovannella Palmieri, Raffaele Addeo and Salvatore Del Prete
Funding Agency and Grant Number
Corresponding Author	Liliana Montella, MD, Medical Oncology Unit, “San Giovanni di Dio” Hospital, via D.Pirozzi 66, Frattamaggiore, 80027 Naples, Italy. lilianamontella@libero.it
Key Words	Hepatocellular carcinoma; Targeted therapy; Pathway; Angiogenesis; Sorafenib
Core Tip	Hepatocellular carcinoma (HCC) is a tumor with increasing incidence and epidemiologic relevance. Advanced hepatocellular carcinoma that is not amenable to radical treatments (i.e., transplantation or surgical resection) has a dismal prognosis (1-2 mo). Sorafenib, a tyrosine kinase inhibitor which targets multiple pro-angiogenic factors, is a cornerstone in the history of HCC treatments. Since the introduction of sorafenib, novel biological drugs have been investigated in hepatocellular carcinoma patients, but no monotherapy or combination therapy has significantly improved outcomes in clinical trials. Insights into tumor gene profile are critical in recognizing various classes of hepatocellular carcinoma in order to help determine which therapeutic approaches will be beneficial. Well-designed clinical trials may disclose differences in efficacy end-points, thus leading the way to clinical use.
Publish Date	2016-07-15 15:38
Citation	Montella L, Palmieri G, Addeo R, Del Prete S. Hepatocellular carcinoma: will novel targeted drugs really impact the next future? World J Gastroenterol 2016; 22(27): 6114-6126
URL	http://www.wjgnet.com/1007-9327/full/v22/i27/6114.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i27.6114

Full Article (PDF)	WJG-22-6114.pdf
Full Article (Word)	WJG-22-6114.doc
Manuscript File	25695-Review.docx
Answering Reviewers	25695-Answering reviewers.pdf
Audio Core Tip	25695-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	25695-Conflict-of-interest statement.pdf
Copyright License Agreement	25695-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25695-Language certificate.pdf
Peer-review Report	25695-Peer-review(s).pdf
Scientific Misconduct Check	25695-Scientific misconduct check.pdf
Scientific Editor Work List	25695-Scientific editor work list.pdf